<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">European S3-Guidelines on the systemic treatment of psoriasis vulgaris -Update 2015 -Short version -EDF in cooperation with EADV and IPC</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">A</forename><surname>Nast</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Evidence Based Medicine</orgName>
								<orgName type="department" key="dep2">Department of Dermatology</orgName>
								<address>
									<settlement>Charit e -Universit€ atsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Gisondi</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Section of Dermatology and Venereology</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">University of Verona</orgName>
								<address>
									<settlement>Verona</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Ormerod</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Aberdeen Royal Infirmary</orgName>
								<address>
									<settlement>Aberdeen</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Saiag</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Service de Dermatologie</orgName>
								<orgName type="institution">Hôpital Ambroise Par e Universit e Paris V</orgName>
								<address>
									<settlement>Boulogne</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Smith</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Clinical Lead for Dermatology</orgName>
								<orgName type="institution">St Johns Institute of Dermatology</orgName>
								<address>
									<settlement>St Thomas&apos; Hospital, London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><forename type="middle">I</forename><surname>Spuls</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Academic Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Arenberger</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Third Faculty of Medicine</orgName>
								<orgName type="department" key="dep2">Department of Dermatology</orgName>
								<orgName type="institution">Charles University</orgName>
								<address>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Bachelez</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Hôpital Saint-Louis</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Barker</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">St. Johns Institute of Dermatology</orgName>
								<address>
									<settlement>St</settlement>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="institution">Thomas&apos; Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Dauden</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Hospital Universitario de la Princesa</orgName>
								<address>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>De Jong</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">University Medical Center Nijmegen St Radboud</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Feist</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Medizinische Klinik mit Schwerpunkt Rheumatologie u. klinische Immonologie</orgName>
								<address>
									<settlement>Charit e -Universit€ atsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Jacobs</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Evidence Based Medicine</orgName>
								<orgName type="department" key="dep2">Department of Dermatology</orgName>
								<address>
									<settlement>Charit e -Universit€ atsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Jobling</surname></persName>
							<affiliation key="aff13">
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Kem</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution">SZTE Borgyogyaszati Klinika</orgName>
								<address>
									<settlement>Szeged</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Maccarone</surname></persName>
							<affiliation key="aff15">
								<address>
									<settlement>Roma</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">U</forename><surname>Mrowietz</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Psoriasis-Center University Medical Center Schleswig Holstein</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Papp</surname></persName>
							<affiliation key="aff17">
								<address>
									<settlement>Waterloo</settlement>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Paul</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Paul Sabatier University</orgName>
								<address>
									<settlement>Toulouse</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Reich</surname></persName>
							<affiliation key="aff19">
								<orgName type="institution">Dermatologikum Hamburg</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Rosumeck</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Evidence Based Medicine</orgName>
								<orgName type="department" key="dep2">Department of Dermatology</orgName>
								<address>
									<settlement>Charit e -Universit€ atsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Talme</surname></persName>
							<affiliation key="aff20">
								<orgName type="department" key="dep1">Section of Dermatology and Venereology</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution" key="instit1">Karolinska Institutet</orgName>
								<orgName type="institution" key="instit2">Karolinska University Hospital</orgName>
								<address>
									<settlement>Huddinge, Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Thio</surname></persName>
							<affiliation key="aff21">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Erasmus University</orgName>
								<address>
									<settlement>Rotterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Van De Kerkhof</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">University Hospital Nijmegen</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Werner</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Evidence Based Medicine</orgName>
								<orgName type="department" key="dep2">Department of Dermatology</orgName>
								<address>
									<settlement>Charit e -Universit€ atsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">N</forename><surname>Yawalkar</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Universit€ atsklinik f€ ur Dermatologie</orgName>
								<address>
									<settlement>Inselspital, Bern</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">European S3-Guidelines on the systemic treatment of psoriasis vulgaris -Update 2015 -Short version -EDF in cooperation with EADV and IPC</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">3D35042C99A069B959F1297668E31E6B</idno>
					<idno type="DOI">10.1111/jdv.13353</idno>
					<note type="submission">Received: 22 June 2015; Accepted: 7 July 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding sources</head><p><s>The guidelines project has kindly been supported by the EDF.</s><s>The financial support did not influence the guidelines development and context.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>This is an executive summary of all consented recommendations of the European Psoriasis Guidelines -Update 2015.</s><s>The long version of this guideline is available online as supplementary file.</s><s>A detailed description of the used methodology can be found in the methods report (DOI: 10.1111/jdv.13353).</s></p><p><s>In brief, available evidence of the efficacy and safety of the systemic treatments for psoriasis including an assessment of the quality of evidence was summarized using GRADE (Grading of Recommen-dations Assessment, Development and Evaluation). <ref type="bibr" target="#b0">1</ref> The end of the literature search was October 12th, 2014.</s><s>Some parts of the guidelines are based on a complete literature review (marked as evidence based), other parts are based on expert consensus only (marked as expert opinion).</s><s>All recommendations (highlighted in grey) were formulated and consented by an expert panel, officially nominated by the European Dermatology Forum (EDF), the European Association for Dermatology and Venereology (EADV) or the International Psoriasis Council (IPC).</s></p><p><s>For the chapters of 'Special considerations and special patient populations', the literature was not systematically assessed and the recommendations are based on expert opinion only.</s></p><p><s>All recommendations were consented using formal consensus methodology (Delphi process or consensus conference with nominal group technique). <ref type="bibr" target="#b1">2,</ref><ref type="bibr">3</ref></s><s>Based on the GRADE approach, the strength of recommendation is expressed by the wording and symbols shown in Table <ref type="table" target="#tab_0">1</ref>.</s></p><p><s>For each recommendation, the strength of consensus in terms of percentage of agreement was measured and documented.</s><s>Three levels of consensus were defined and distinguished: 'strong consensus' (agreement of &gt;90% of the members of the expert group), 'consensus' (75-89% agreement) and 'weak consensus' (50-74% agreement).</s></p><p><s>The guidelines have a validity until 31.12.2019.</s><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/Skindex-29 or -17)</s></p><p><s>• History and clinical examination should focus on musculoskeletal problems.</s><s>If patient reports complaints, further imaging investigation may be performed</s></p><p><s>• Exclude pregnancy/breastfeeding: patient must be informed explicitly and extensively about the teratogenic risk of the medication, the necessity of effective long-term contraception (at least two years after cessation of treatment) and the possible consequences of a pregnancy while taking retinoids; written documentation of this informational interview</s></p><p><s>• Note that during and up to one year after treatment, blood donation is not permitted • Laboratory controls (see Table <ref type="table" target="#tab_1">2</ref>)</s></p><p><s>During treatment</s></p><p><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/Skindex-29 or -17)</s></p><p><s>• Take capsules with a fatty meal or with whole milk • Avoidance of pregnancy is mandatory.</s><s>Start treatment on second or third day of the menstrual cycle, after satisfactory contraception for at least one month prior to treatment.</s><s>Double contraception is recommended (e.g.</s><s>condom + pill; IUD/ Nuva Ring + pill; cave: no low-dosed progesterone preparations/mini-pills) during and up to two years after the end of therapy; effectiveness of oral contraceptives is reduced by acitretin</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Therapeutic recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Therapeutic combinations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ciclosporin</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Instructions for use</head><p><s>Pre-treatment</s></p><p><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/ Skindex-29 or -17)</s></p><p><s>• History and clinical examination should focus on previous and concomitant diseases (e.g.</s><s>arterial hypertension; severe infections; malignancies, including cutaneous malignancies; renal and liver diseases) and concomitant medication (see Drug interactions, long version)</s></p><p><s>• Measurement of blood pressure on two separate occasions • Laboratory controls (see Table <ref type="table" target="#tab_2">3</ref>)</s></p><p><s>• Reliable contraception (cave: reduced efficacy of progesterone-containing contraceptives)</s></p><p><s>• Regular gynaecologic screening according to national guidelines • Consultation on vaccination; susceptibility to infections (take infections seriously, seek medical attention promptly); drug interactions (inform other treating physicians about therapy); avoidance of excessive sun exposure; use of sunscreens</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>During treatment</head><p><s>In uncomplicated long-term therapy with low-dose ciclosporin (CSA; 2.5-3 mg/kg daily), follow-up intervals may be extended to two months or more.</s><s>Shorter intervals may be needed in patients with risk factors, dose increases, or those who must take concomitant medications that are likely to contribute to ADR.</s><s>In selected patients with intermittent and short-term treatment, less strict monitoring (regular checking of blood pressure and creatinine level) may be sufficient.</s></p><p><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/Skindex-29 or -17)</s></p><p><s>• Clinical examination should focus on the status of skin and mucous membranes (hypertrichosis, gingival changes), signs of infections, gastrointestinal or neurological symptoms (tremor, dysaesthesia) and musculoskeletal/joint pain</s></p><p><s>• Repeat recommendation for sun avoidance and sun protection • Check of concomitant medication • Measurement of blood pressure • Laboratory controls (see Table <ref type="table" target="#tab_2">3</ref>)</s></p><p><s>• Reliable contraception • Regular gynaecologic screening according to national guidelines • If creatinine is significantly elevated and/or patient on therapy for &gt;1 year, perform creatinine clearance (or creatinine-EDTA clearance where available).</s></p><p><s>• Determination of the CSA level is recommended in individual cases.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Post-treatment</head><p><s>• After discontinuation of CSA, patients should be followed up for skin cancer, especially in case of extensive prior therapeutic or natural UV exposure.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strength of consensus Comment</head><p><s>If a short course for induction treatment is intended we recommend CSA.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Evidence and consensus based</head><p><s>For long-term treatment we suggest CSA only in selected patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑ Strong consensus Expert opinion</head><p><s>In case of continuous long-term treatment, we suggest CSA for a maximum of up to two years.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head><p><s>In case a longer treatment is needed, we suggest the consultation with a nephrologist.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head><p><s>Based on weighting of risk and benefit we suggest using CSA with a starting dose of 2.5 mg/kg bodyweight QD for up to four weeks, with a dosage increase up to 5 mg/kg bodyweight once daily thereafter.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Weak consensus</head><p><s>Evidence and consensus based</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Therapeutic combinations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fumaric acid esters</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Instructions for use</head><p><s>Pre-treatment</s></p><p><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/Skindex-29 or -17)</s></p><p><s>• History and clinical examination • Laboratory controls (see Table <ref type="table" target="#tab_3">4</ref>)</s></p><p><s>During treatment</s></p><p><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/Skindex-29 or -17)</s></p><p><s>• Clinical examination • Laboratory controls (see Table <ref type="table" target="#tab_3">4</ref>)</s></p><p><s>Post-treatment</s></p><p><s>• None.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Therapeutic recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation Strength of consensus Comment</head><p><s>We recommend fumaric acid esters for the induction treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑ Consensus Evidence and consensus based</head><p><s>We recommend fumaric acid esters for the long-term treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑ Consensus Expert opinion</head><p><s>We recommend fumaric acid esters with a slow increase dosing regimen.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Therapeutic combinations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methotrexate</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Instructions for use</head><p><s>Pre-treatment</s></p><p><s>• History and clinical examination • Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/Skindex-29 or -17)</s></p><p><s>• Laboratory parameters (see Table <ref type="table" target="#tab_5">5</ref>)</s></p><p><s>• Chest X-ray • Contraception in women of child-bearing age (starting after menstruation), and also in men • If abnormalities in liver screening are found, refer patient to specialist for further evaluation During treatment</s></p><p><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/Skindex-29 or -17)</s></p><p><s>• Check concomitant medication • Clinical examination • Laboratory controls (see Table <ref type="table" target="#tab_5">5</ref>)</s></p><p><s>• Contraception in women of child-bearing age, and also in men • 5 mg folic acid once weekly, 24 h after MTX</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biological therapy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adalimumab</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Instructions for use</head><p><s>Pre-treatment</s></p><p><s>• Physicians are encouraged to enrol their patients in a registry (if available)</s></p><p><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/Skindex-29 or -17)</s></p><p><s>• History and clinical examination should focus on prior exposure to treatments, malignancies, infections, congestive heart failure (CHF) and neurological disease or symptoms</s></p><p><s>• Recommended measures include:</s></p><p><s>-Check for skin cancer -Check for lymphadenopathy -Laboratory parameters (see Table <ref type="table" target="#tab_6">6</ref>) -Exclusion of tuberculosis (see chapter 5.1 in long version) -Check for evidence of active infection • Contraception</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>During treatment</head><p><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/Skindex-29 or -17)</s></p><p><s>• Clinical examination should focus on malignancies, risk factors for serious infections, congestive heart failure and neurological symptoms</s></p><p><s>• Recommended measures include:</s></p><p><s>-Check for skin cancer -Check for lymphadenopathy -Laboratory parameters (see • After discontinuation of adalimumab, patients should be followed up with medical history and physical examination • Reliable contraception until five months after treatment, if applicable (according to the label)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Therapeutic recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Therapeutic combinations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation Strength of consensus Comment</head><p><s>We recommend adalimumab as second-line medication* for the induction and long-term treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Evidence and consensus based</head><p><s>We recommend using adalimumab with an initial loading dose of 80 mg for week 1, followed by 40 mg every other week.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Etanercept</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Instructions for use</head><p><s>Pre-treatment</s></p><p><s>• Physicians are encouraged to enrol their patients in a registry (if available)</s></p><p><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/Skindex-29 or -17)</s></p><p><s>• History and clinical examination should focus on prior exposure to treatments, malignancies, infection, congestive heart failure and neurological symptoms</s></p><p><s>• Recommended measures include:</s></p><p><s>-Check for malignancy, mainly skin cancer and pre-malignant lesions -Check for lymphadenopathy -Laboratory parameters (see Table <ref type="table" target="#tab_9">7</ref>) -Exclusion of tuberculosis (see chapter 5.1 in long version) -Check for evidence of active infection • Contraception</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>During treatment</head><p><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis) • HRQoL such as (DLQI/Skindex-29 or -17)</s></p><p><s>• Clinical examination should focus on lymphadenopathy, malignancies, especially skin cancer, premalignant lesions, risk factors for serious infections, congestive heart failure and neurological symptoms</s></p><p><s>• Recommended measures include:</s></p><p><s>-Laboratory parameters (see Table <ref type="table" target="#tab_9">7</ref>)</s></p><formula xml:id="formula_0">• Contraception Post-treatment</formula><p><s>• After discontinuation of etanercept, patients should be followed up with medical history and physical examination.</s></p><p><s>• Women of childbearing potential should be advised to use appropriate contraception to avoid becoming pregnant for three weeks after discontinuation of therapy.</s><s>Not all tests may be necessary for all patients.</s><s>Patient history, risk exposure and patient characteristics have to be taken into account.</s><s>Further specific testing may be required according to clinical signs, risk and exposure.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strength of consensus Comment</head><p><s>We recommend etanercept as second-line* medication for the induction and long-term treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Evidence and consensus based</head><p><s>In general, a starting dose of 50 mg once or twice weekly is used depending on individual factors.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statement</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Therapeutic recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Therapeutic combinations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Infliximab</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Instructions for use</head><p><s>Pre-treatment</s></p><p><s>• Physicians are encouraged to enrol their patients in a registry (if available)</s></p><p><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/Skindex-29 or -17)</s></p><p><s>• History focusing on prior exposure to treatments.</s><s>History and clinical examination should focus on malignancies, infection, congestive heart failure and neurological symptoms</s></p><p><s>• Recommended measures include:</s></p><p><s>-Check for skin cancer -Check for lymphoadenopathy -Laboratory parameters (see Table <ref type="table" target="#tab_11">8</ref>) -Exclusion of tuberculosis (see chapter 5.1 in long version) -Check for evidence of active infection</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>• Contraception</head><p><s>During treatment</s></p><p><s>• Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/ Skindex-29 or -17)</s></p><p><s>• Clinical examination should focus on malignancies, risk factors for serious infections, congestive heart failure and neurological symptoms</s></p><p><s>• Recommended measures include:</s></p><p><s>-Check for skin cancer -Check for lymphoadenopathy -Laboratory parameters (see  Not all tests may be necessary for all patients.</s><s>Patient history, risk exposure and patient characteristics have to be taken into account.</s><s>Further specific testing may be required according to clinical signs, risk and exposure.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation Strength of consensus Comment</head><p><s>We recommend infliximab as second-line* medication for the induction and long-term treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Evidence and consensus based</head><p><s>We recommend using infliximab 5 mg/kg bodyweight continuously every eight weeks during long-term treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ustekinumab</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Instructions for use</head><p><s>Pre-treatment</s></p><p><s>• Physicians are encouraged to enrol their patients in a registry (if available)</s></p><p><s>• Objective assessment of disease (such as PASI/BSA/PGA; arthritis)</s></p><p><s>• HRQoL (such as DLQI/Skindex-29 or -17)</s></p><p><s>• History and clinical examination focusing on previous treatment exposure, UV light, malignancies, infections • Recommended measures include:</s></p><p><s>-Check for skin cancer -Check for lymphadenopathy -Laboratory parameters (see Table <ref type="table" target="#tab_14">9</ref>) -Exclusion of tuberculosis (see chapter 5.1 in long version) -Evaluation of comorbidities including cardiovascular risk factors -Check for evidence of active infection • Contraception</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>During treatment</head><p><s>• Objective assessment of disease (such as PASI/BSA/PGA; arthritis) • Patient oriented outcomes such as pruritus, DLQI and Skindex-29 or -17 • History and clinical examination focusing on malignancies and infections • Recommended measures include:</s></p><p><s>-Check for skin cancer and lymphadenopathy -Pregnancy -Evaluation of treatment adherence</s></p><p><s>Post-treatment • Patients should be followed up with medical history and clinical examination • Contraception to be maintained for 15 weeks Not all tests may be necessary for all patients.</s><s>Patient history, risk exposure and patient characteristics have to be taken into account.</s><s>Further specific testing may be required according to clinical signs, risk and exposure.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Special considerations and special patient populations</head><p><s>Tuberculosis (TB) screening before and during biologic treatment Hepatitis/other hepatological dysfunctions</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation Strength of consensus Comment</head><p><s>We recommend ustekinumab as second-line medication* for the induction and long-term treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Evidence and consensus based</head><p><s>We suggest using 45 mg for patients with a bodyweight of ≤100 kg and mg ustekinumab for patients with a bodyweight of &gt;100 kg.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strength of consensus Comment</head><p><s>We recommend to do tuberculosis screening according to local regulations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑ Strong consensus Expert opinion</head><p><s>For pre-screening, we recommend anamnesis including tuberculosis history; a chest X-ray; TST and/or IGRA.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>We recommend remaining alert to the possibility of tuberculosis infection during therapy.</s><s>This includes taking medical history and might include tuberculosis testing.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation Strength of consensus Comment</head><p><s>We recommend to screen patients for hepatitis B and hepatitis C before starting treatment with a biologic or methotrexate.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head><p><s>We recommend to screen patients for hepatitis B before starting treatment with ciclosporin.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑ Consensus Expert opinion</head><p><s>If a positive marker is found, or the patient is known to have had prior infection we recommend to consult a gastroenterologist with an interest in hepatology.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Weak consensus Expert opinion</head><p><s>We recommend to record all cases of reactivation/ exacerbation via drug registries.</s><s>↑↑ Consensus Expert opinion</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HIV</head><p><s>Malignancies including lymphoma and skin cancer</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neurological disease</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation Strength of consensus Comment</head><p><s>We recommend the combination of anti-retroviral therapy with topical therapies (steroids, vitamin D derivatives, or combination of both) as first-line treatment strategy for mild to moderate psoriasis in HIV-infected patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>For moderate-to-severe psoriasis, we recommend highly active anti-retroviral therapy with skin-directed therapies, e.g.</s><s>topicals and/or phototherapy (narrowband UVB mainly) as firstline strategy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>We suggest acitretin as second-line treatment in addition to highly active anti-retroviral therapy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>We suggest using methotrexate or ciclopsorin or biologics only in patients with severe, refactory psoriasis with well controlled HIV disease using HAART, in collaboration with a specialist on HIV medicine.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>In cases showing lack of response, intolerance, or contraindication to conventional systemic immunosuppressants, we suggest to consider biologics.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head><p><s>We suggest using etanercept as biologic of choice in patients with severe, refactory psoriasis with well controlled HIV disease using HAART.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation Strength of consensus Comment</head><p><s>For patients with recent malignancy we recommend topical therapies, phototherapy (narrow band UVB) * and/or acitretin.</s><s>*except cutaneous malignancies</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>In case of inadequate response to topical therapies, phototherapy, (narrow band UVB) and/ or acitretin we suggest using MTX.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head><p><s>We recommend to discuss the decision to initiate immunosuppressive therapies, in psoriasis patients with a current or recent diagnosis of cancer in the previous five years case by case with cancer specialists and to reach an informed decision, respecting the patient's preference.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head><p><s>The elements to be taken into account for the shared decision are the type and staging of cancer, the risk of recurrence and the burden of psoriasis in the individual patient.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statement Strong consensus Expert opinion</head><p><s>In some cancers with relatively good prognosis, where flares of psoriasis cannot be controlled by other therapies, we suggest to consider earlier introduction of immunosuppressive therapies.</s><s>In this case, we suggest methotrexate as the preferred systemic agent to be used.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>In patients with concurrent cancer treatment who are treated with immunosuppressive agents, we recommend to perform a search for pharmacological interactions in coordination with the oncologist.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation Strength of consensus Comment</head><p><s>We do not recommend TNF antagonist therapy in people with diagnosis of multiple sclerosis or other demyelinating disease.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↓↓</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>We recommend caution using TNF antagonist therapy in people with a first degree relative with multiple sclerosis or other demyelinating disease.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation Strength of consensus Comment</head><p><s>We suggest not using ciclosporin as a first-line treatment in patients with diabetes and/or features of the metabolic syndrome.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↓</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head><p><s>We suggest not using acitretin as a first-line treatment in patients with dyslipidaemia.</s><s>↓ Consensus Expert opinion</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation Strength of consensus Comment</head><p><s>We recommend ensuring an accurate assessment of renal function in any patient with known or suspected chronic kidney disease prior to therapy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>We recommend working in collaboration with the nephrologist when prescribing systemic therapy in any patient with chronic kidney disease of stage 3 or more.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>We suggest using methotrexate, acitretin, or biological therapy in people with chronic kidney disease stage 2-3.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head><p><s>We recommend using a reduced dose of methotrexate in people with chronic kidney disease stage 3.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head><p><s>In people with chronic kidney disease stage 4-5 biologics can be used.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statement Strong consensus Expert opinion</head><p><s>We recommend not using ciclosporin or fumaric acid esters in chronic kidney disease stage 3 or more.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↓↓</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>We recommend not using methotrexate in chronic kidney disease 4 or 5.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↓↓ Strong consensus Expert opinion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation Strength of consensus Comment</head><p><s>We recommend to advise the use of topical emollients, and low to moderate strength corticosteroids of short duration as first-line therapy in women with a wish for pregnancy in the near future or who are pregnant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head><p><s>We recommend phototherapy with narrow band UVB for women who are inadequately controlled by emollients and topical steroids who wish to become pregnant or who are pregnant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>For pregnant women with severe psoriasis requiring systemic therapy for which the benefits outweigh the risk, we suggest to consider etanercept.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>We recommend not using acitretin and methotrexate in women considering becoming pregnant or who are pregnant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Psoriatic arthritis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Newly approved medications and treatments in the pipeline</head><p><s>The field of psoriasis treatments is evolving rapidly and several new treatments have been developed.</s><s>For any guideline, it is a challenge to be up to date with the rapidly changing market of psoriasis treatments.</s><s>New medications with very little use during regular clinical practice are difficult to assess with expert opinion knowledge.</s><s>The guideline group has decided to focus on the licensed treatment options at the time point of the consensus conference.</s><s>The group decided against a prospective inclusion of new drugs that are likely to be licensed in the near future, especially also in the light of lack of expert experience with these new drugs.</s><s>Since the cut off date for inclusion of approved medications in Europe (October 2014), secukinumab and apremilast have been granted market authorization by EMA. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref></s><s>An update including newly approved medications is currently under preparation.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref>ength of recommendations: wording, symbols and implications4,5</s></p></div></figDesc><table><row><cell>Strength</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Recommended lab controlsacitretinNot all tests may be necessary for all patients.</s><s>Patient history, risk exposure and patient characteristics have to be taken into account.</s><s>Further specific testing may be required according to clinical signs, risk and exposure.</s></p></div></figDesc><table><row><cell>Parameter</cell><cell cols="2">Period in weeks</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">Pre-treatment</cell><cell>1</cell><cell>2</cell><cell>4</cell><cell>8</cell><cell>12</cell><cell>16</cell></row><row><cell>Blood count*</cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>x</cell><cell>x</cell></row><row><cell>Liver enzymes**</cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell>x</cell><cell>x</cell></row><row><cell>Serum creatinine</cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pregnancy test (urine)</cell><cell>x</cell><cell></cell><cell cols="4">Monthly up to 2 years after therapy (see national regulations)</cell></row><row><cell>Fasting blood glucose</cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Triglycerides, cholesterol, HDL</cell><cell>x</cell><cell></cell><cell></cell><cell></cell><cell>x</cell><cell></cell><cell>x</cell></row><row><cell></cell><cell></cell><cell></cell><cell>↑</cell><cell>Consensus</cell><cell></cell><cell cols="2">Expert opinion</cell></row><row><cell>Recommendation</cell><cell></cell><cell>Strength of consensus</cell><cell></cell><cell>Comments</cell><cell></cell><cell></cell></row><row><cell>Adalimumab</cell><cell>o</cell><cell>Consensus</cell><cell></cell><cell cols="2">No evidence available</cell><cell></cell></row><row><cell>Ciclosporin</cell><cell>↓</cell><cell>Strong consensus</cell><cell></cell><cell cols="4">Expert opinion: competition cytochrome P450 inactivation</cell></row><row><cell>Etanercept</cell><cell>↑</cell><cell>Consensus</cell><cell></cell><cell cols="4">Expert opinion: good safety profile assumed, possibly increased efficacy</cell></row><row><cell>Fumaric acid esters</cell><cell>o</cell><cell>Consensus</cell><cell></cell><cell cols="2">No evidence available</cell><cell></cell></row><row><cell>Infliximab</cell><cell>o</cell><cell>Consensus</cell><cell></cell><cell cols="2">No evidence available</cell><cell></cell></row><row><cell>Methotrexate</cell><cell>↓</cell><cell>Strong consensus</cell><cell></cell><cell cols="4">Expert opinion: increased risk of hepatotoxicity possible</cell></row><row><cell>Ustekinumab</cell><cell>o</cell><cell>Consensus</cell><cell></cell><cell cols="2">No evidence available</cell><cell></cell></row></table><note><p><s>*Hb, Hct, leucocytes, platelets.**AST,ALT,AP,cGT.RecommendationStrength of consensus CommentBased on the available evidence we cannot make a recommendation for or against the use of acitretin as a monotherapy.oConsensusEvidence</s><s>and consensus basedBased on clinical experience and depending on the most important outcome for the individual patient, we suggest a low dose (20-30 mg daily) with respect to tolerability and a high dose (&gt;30 mg daily) with respect to efficacy.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>Recommended lab controlsciclosporinNot</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Diagnostics</cell><cell>Period in weeks</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>Pre-treatment</cell><cell>2</cell><cell>4</cell><cell>8</cell><cell>12</cell><cell>16</cell></row><row><cell></cell><cell cols="2">Full blood count*</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell></cell><cell cols="2">Liver values**</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell></cell><cell cols="2">Electrolytes***</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell></cell><cell cols="2">Serum creatinine</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell></cell><cell cols="2">Urine status</cell><cell>x</cell><cell></cell><cell>x</cell><cell></cell><cell>x</cell></row><row><cell></cell><cell cols="2">Uric acid</cell><cell>x</cell><cell></cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell></cell><cell cols="2">Pregnancy test (urine)</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">Cholesterol, triglycerides</cell><cell>x****</cell><cell></cell><cell></cell><cell>x</cell><cell>x</cell></row><row><cell></cell><cell cols="2">Magnesium*****</cell><cell>x</cell><cell></cell><cell></cell><cell>x</cell><cell>x</cell></row><row><cell></cell><cell cols="2">HBV/HCV</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>HIV</cell><cell></cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Therapeutic recommendations</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Recommendation</cell><cell></cell><cell>Strength of consensus</cell><cell>Comments</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Acitretin</cell><cell>↓</cell><cell>Strong consensus</cell><cell cols="5">Expert opinion: competition cytochrome P450 inactivation</cell></row><row><cell>Adalimumab</cell><cell>↓</cell><cell>Consensus</cell><cell cols="5">Expert opinion: increased risk of immunosuppression</cell></row><row><cell>Etanercept</cell><cell>↓</cell><cell>Consensus</cell><cell cols="5">Expert opinion: increased risk of immunosuppression</cell></row><row><cell>Fumaric acid esters</cell><cell>o</cell><cell>Consensus</cell><cell cols="2">No evidence available</cell><cell></cell><cell></cell></row><row><cell>Infliximab</cell><cell>↓</cell><cell>Consensus</cell><cell cols="5">Expert opinion: increased risk of immunosuppression</cell></row><row><cell>Methotrexate</cell><cell>↓</cell><cell>Weak consensus</cell><cell cols="5">Expert opinion: increased risk of immunosuppression</cell></row></table><note><p><s>all tests may be necessary for all patients.Patient history, risk exposure and patient characteristics have to be taken into account.Further specific testing may be required according to clinical signs, risk and exposure.*Erythrocytes,</s><s>leucocytes, platelets.</s><s>**Transaminases, AP, cGT, bilirubin.</s><s>***Sodium, potassium.</s><s>****Recommended two weeks before and on the day of treatment initiation (fasting).</s><s>*****Only with indication (muscle cramps).</s><s>Ustekinumab ↓ Consensus Expert opinion: increased immunosuppression, anecdotal evidence of increased toxicity</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc><div><p><s>Recommended lab controlsfumaric acid esters</s></p></div></figDesc><table><row><cell>Parameter</cell><cell>Period in weeks</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Pre-treatment</cell><cell>Month 1</cell><cell>Every 4 weeks until</cell><cell>Thereafter</cell></row><row><cell></cell><cell></cell><cell></cell><cell>month 4</cell><cell></cell></row><row><cell>Liver enzymes</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>every 8 weeks</cell></row><row><cell>Serum creatinine</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>every 8 weeks</cell></row><row><cell>Urine status</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>every 8 weeks</cell></row><row><cell>Pregnancy test</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Blood count*</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>every 4 weeks*</cell></row></table><note><p><s>*Not all tests may be necessary for all patients.Patient history, risk exposure and patient characteristics have to be taken into account.Further specific testing may be required according to clinical signs, risk and exposure.*If</s><s>leukocytes are &lt;3000/ll, fumarate therapy needs to be stopped.</s><s>If lymphocytes are &lt;700/ll, patients should be kept on half of the last dose for 2-4 weeks and stopped if lymphocytes remain below 700/ll; if lymphocytes are &lt;500/ll, treatment must be terminated.</s><s>**Frequency of lab control of blood count was a matter of debate, including repeated Delphi voting.</s><s>No strong consensus was achieved, the recommendation passed with 'weak consensus' (63%).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 5</head><label>5</label><figDesc><div><p><s>Recommended lab controlsmethotrexateNot all tests may be necessary for all patients.</s><s>Patient history, risk exposure and patient characteristics have to be taken into account.</s><s>Further specific testing may be required according to clinical signs, risk and exposure.</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Parameter</cell><cell cols="3">Period in weeks/months</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">Pre-treatment</cell><cell>After first</cell><cell>During first two months,</cell><cell>Thereafter,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>week</cell><cell>1 3 every 2 weeks</cell><cell>every 2-3 months</cell></row><row><cell></cell><cell cols="2">Blood count*</cell><cell>x</cell><cell></cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell></cell><cell cols="2">Liver enzymes</cell><cell>x</cell><cell></cell><cell>x</cell><cell>x</cell></row><row><cell></cell><cell cols="2">Serum creatinine</cell><cell>x</cell><cell></cell><cell>x</cell><cell>x</cell></row><row><cell></cell><cell cols="2">Urine status</cell><cell>x</cell><cell></cell><cell>x</cell><cell>x</cell></row><row><cell></cell><cell cols="2">Pregnancy test (urine)</cell><cell>x</cell><cell></cell></row><row><cell></cell><cell cols="2">HBV/HCV</cell><cell>x</cell><cell></cell></row><row><cell></cell><cell>HIV</cell><cell></cell><cell>x</cell><cell></cell></row><row><cell></cell><cell cols="2">Serum albumin**</cell><cell>x</cell><cell></cell><cell>x</cell><cell>x</cell></row><row><cell></cell><cell cols="2">PIIINP where available</cell><cell>x</cell><cell></cell><cell>Every 3 months***</cell></row><row><cell cols="3">Therapeutic recommendations</cell><cell></cell><cell></cell></row><row><cell>Recommendation</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Strength of consensus</cell><cell>Comment</cell></row><row><cell cols="5">We recommend MTX for the induction and long-term treatment.</cell><cell>↑↑</cell><cell>Strong consensus</cell><cell>Evidence and consensus based</cell></row><row><cell cols="6">Methotrexate can be given by oral or subcutaneous delivery. In general, a</cell><cell>Statement</cell><cell>Strong consensus</cell><cell>Expert opinion</cell></row><row><cell cols="6">starting dose of 15 mg/week is used but individual dosages can range from</cell></row><row><cell cols="3">5 to 25 mg/week depending on individual factors.</cell><cell></cell><cell></cell></row><row><cell cols="3">Therapeutic combinations</cell><cell></cell><cell></cell></row><row><cell>Recommendation</cell><cell></cell><cell cols="2">Strength of consensus</cell><cell cols="2">Comments</cell></row><row><cell>Acitretin</cell><cell>↓</cell><cell>Strong consensus</cell><cell></cell><cell cols="2">Expert opinion: increased risk of hepatotoxicity possible</cell></row><row><cell>Adalimumab</cell><cell>↑</cell><cell>Consensus</cell><cell></cell><cell cols="2">Expert opinion: combination widely used in rheumatology; combination with low-dose MTX (e.g.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">7.5-10 mg/week is likely sufficient to reduce formation of anti-drug antibodies (ADA) and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">increase trough levels of adalimumab)</cell></row><row><cell>Ciclosporin</cell><cell>↓</cell><cell>Weak consensus</cell><cell></cell><cell cols="2">Expert opinion: increased risk of immunosuppression</cell></row><row><cell>Etanercept</cell><cell>↑</cell><cell>Consensus</cell><cell></cell><cell cols="2">Evidence (additional benefit of adding MTX to etanercept compared to etanercept monotherapy)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">and consensus based</cell></row><row><cell>Fumaric acid esters</cell><cell>↓</cell><cell>Consensus</cell><cell></cell><cell cols="2">Expert opinion: increased risk of immunosuppression</cell></row><row><cell>Infliximab</cell><cell>↑</cell><cell>Consensus</cell><cell></cell><cell cols="2">Expert opinion: combination widely used in rheumatology; combination with low-dose MTX (e.g.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">7.5-10 mg/week is likely sufficient to reduce formation of ADA and increase trough levels of</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">infliximab)</cell></row><row><cell>Ustekinumab</cell><cell>o</cell><cell>Consensus</cell><cell></cell><cell cols="2">No evidence available</cell></row></table><note><p><s>*If blood leucocytes &lt;3.0, neutrophils &lt;1.0, thrombocytes &lt;100, or liver enzymes &gt;2 9 baseline values, decrease the dose or discontinue the medication.</s><s>**In selected cases (e.g. in cases with suspected hypoalbuminaemia or in patients using other drugs with high binding affinity for serum albumin).</s><s>***Liver biopsy when necessary in selected cases; should be considered, for example, in patients with persistently abnormal PIIINP (&gt;4.2 mcg/l in at least three samples over a 12-month period).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 6 )</head><label>6</label><figDesc><div><p><s>• Contraception</s></p></div></figDesc><table><row><cell>Post-treatment</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 6</head><label>6</label><figDesc><div><p><s>Recommended lab controlsadalimumabNot all tests may be necessary for all patients.</s><s>Patient history, risk exposure and patient characteristics have to be taken into account.</s><s>Further specific testing may be required according to clinical signs, risk and exposure.</s></p></div></figDesc><table><row><cell>Parameter</cell><cell>Period in weeks</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Pre-treatment</cell><cell>4</cell><cell>12</cell><cell>Thereafter,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>every 3-6 months</cell></row><row><cell>Full blood count</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell>Liver enzymes</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell>Serum creatinine</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell>Urine status</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell>Pregnancy test</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell>(urine)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CRP</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell>HBV/HCV</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell>HIV</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_9"><head>Table 7</head><label>7</label><figDesc><div><p><s>Recommended lab controlsetanercept</s></p></div></figDesc><table><row><cell>Parameter</cell><cell>Period in weeks</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Pre-treatment</cell><cell>4</cell><cell>12</cell><cell>Thereafter,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>every 3-6 months</cell></row><row><cell>Full blood count</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell>Liver enzymes</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell>Serum creatinine</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell>Urine status</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pregnancy test (urine)</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CRP</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell>HBV/HCV</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell>HIV</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_11"><head>Table 8 )</head><label>8</label><figDesc><div><p><s>• Contraception</s></p></div></figDesc><table><row><cell>Therapeutic recommendations</cell></row><row><cell>Therapeutic combinations</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_12"><head>Table 8</head><label>8</label><figDesc><div><p><s>Recommended lab controlsinfliximab</s></p></div></figDesc><table><row><cell>Parameter</cell><cell>Period in weeks</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Pre-treatment</cell><cell>2</cell><cell>6</cell><cell>Thereafter, prior</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>to each infusion</cell></row><row><cell>Full blood count</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell>Liver enzymes</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell>Serum creatinine</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell>Urine status</cell><cell>x</cell><cell>x</cell><cell>x</cell><cell>x</cell></row><row><cell>Pregnancy test (urine)</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CRP</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell>HBV/HCV</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row><row><cell>HIV</cell><cell>x</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_14"><head>Table 9</head><label>9</label><figDesc><div><p><s>Recommended lab controlsustekinumab</s></p></div></figDesc><table><row><cell>Parameter</cell><cell>Period in weeks/months</cell><cell></cell></row><row><cell></cell><cell>Pre-treatment</cell><cell>Thereafter every 3-6 months</cell></row><row><cell>Full blood count</cell><cell>x</cell><cell>x</cell></row><row><cell>Liver enzymes</cell><cell>x</cell><cell>x</cell></row><row><cell>Serum creatinine</cell><cell>x</cell><cell>x</cell></row><row><cell>Urine status</cell><cell>x</cell><cell>x</cell></row><row><cell>Pregnancy test (urine)</cell><cell>x</cell><cell></cell></row><row><cell>CRP</cell><cell>x</cell><cell></cell></row><row><cell>HBV/HCV</cell><cell>x</cell><cell></cell></row><row><cell>HIV</cell><cell>x</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_15"><head></head><label></label><figDesc><div><p><s>Strong consensusEvidence and consensus based *if phototherapy and conventional systemic agents were inadequate in response or if they are contraindicated or not tolerated (the label currently states: if PUVA or other systemic therapies including ciclosporin, methotrexate were inadequate in response or if they are contraindicated or not tolerated).</s><s>No strong consensus on definition of 'second-line' for ustekinumab was achieved, the definition passed with 'weak consensus' (55%).</s></p></div></figDesc><table><row><cell>Recommendation</cell><cell></cell><cell>Strength of consensus</cell><cell>Comments</cell></row><row><cell>Acitretin</cell><cell>o</cell><cell>Consensus</cell><cell>No evidence available</cell></row><row><cell>Adalimuab</cell><cell>↓</cell><cell>Consensus</cell><cell>Expert opinion: increased risk of immunosuppression</cell></row><row><cell>Ciclosporin</cell><cell>↓</cell><cell>Consensus</cell><cell>Expert opinion: increased immunosuppression, anecdotal</cell></row><row><cell></cell><cell></cell><cell></cell><cell>evidence of increased toxicity</cell></row><row><cell>Etanercept</cell><cell>↓</cell><cell>Consensus</cell><cell>Expert opinion: increased risk of immunosuppression</cell></row><row><cell>Fumaric acid esters</cell><cell>o</cell><cell>Consensus</cell><cell>No evidence available</cell></row><row><cell>Infliximab</cell><cell>↓</cell><cell>Consensus</cell><cell>Expert opinion: increased risk of immunosuppression</cell></row><row><cell>Methotrexate</cell><cell>o</cell><cell>Consensus</cell><cell>No evidence available</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2015 European Academy of Dermatology and Venereology JEADV 2015, 29, 2277-2294</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2015 European Academy of Dermatology and Venereology</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting information</head><p><s>Additional Supporting Information may be found in the online version of this article: Data S1.</s><s>Long version: European S3-Guidelines on the systemic treatment of psoriasis vulgarisupdate 2015 -EDF in cooperation with EADV and IPC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation Strength of consensus Comment</head><p><s>For relief of symptoms of psoriatic arthritis, we recommend NSAIDs.</s><s>As a monotherapy, we recommend NSAIDs for patients with mild and non-erosive articular as well as para-articular involvement.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strong consensus Expert opinion</head><p><s>In patients with active joint involvement despite the usage of NSAIDs and potential poor prognosis due to polyarthritis, increased inflammatory markers and erosive changes, we recommend to start synthetic DMARDs early to prevent progression of disease and erosive destruction of joints.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>↑↑</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consensus Expert opinion</head><p><s>For inadequately responding patients after at least one synthetic DMARD, we recommend the use of biological DMARDs in combination with synthetic DMARDs or as monotherapy.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Grading quality of evidence and strength of recommendations</title>
		<author>
			<persName><forename type="first">D</forename><surname>Atkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Best</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Briss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">328</biblScope>
			<biblScope unit="page">1490</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Consensus methods for medical and health services research</title>
		<author>
			<persName><forename type="first">J</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hunter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">311</biblScope>
			<biblScope unit="page" from="376" to="380" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Consensus development methods, and their use in clinical guideline development: a review</title>
		<author>
			<persName><forename type="first">E</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lamping</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mckee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sanderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Technol Assess</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">88</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation&apos;s direction and strength</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schunemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="726" to="735" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations</title>
		<author>
			<persName><forename type="first">J</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="719" to="725" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">CHMP summary of positive opinion for Cosentyx</title>
		<author>
			<persName><forename type="first">Agency</forename><surname>European Medicines</surname></persName>
		</author>
		<ptr target="http://www.ema.europa.eu:80/ema/index.jsp?curl=pages/medicines/human/medicines/003729/smops/Positive/human_smop_000755.jsp&amp;mid=WC0b01ac058001d127" />
		<imprint>
			<date type="published" when="2014-02-20">2014. February 20. 2015</date>
		</imprint>
	</monogr>
	<note>last accessed</note>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">CHMP summary of positive opinion for Otezla</title>
		<author>
			<persName><forename type="first">Agency</forename><surname>European Medicines</surname></persName>
		</author>
		<ptr target="http://www.ema.europa.eu/ema/in-dex.jsp?curl=pages/medicines/human/medicines/003746/smops/Positive/human_smop_000754.jsp&amp;mid=WC0b01ac058001d127" />
		<imprint>
			<date type="published" when="2014-02-20">2014. February 20. 2015</date>
		</imprint>
	</monogr>
	<note>last accessed</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
